Interventions for portal hypertension in patients with portal vein occlusion and possible effects of a stent-graft on hepatic circulation

Keussen, Inger

2007

Link to publication

Citation for published version (APA):
INTERVENTIONS FOR PORTAL HYPERTENSION IN PATIENTS WITH PORTAL VEIN OCCLUSION AND POSSIBLE EFFECTS OF A STENT-GRAFT ON HEPATIC CIRCULATION
Interventions for Portal Hypertension in Patients with Portal Vein Occlusion and Possible Effects of a Stent-graft on Hepatic Circulation

Inger Keussen
Abstract

Symptomatic portal hypertension (PH), is often treated with transjugular intrahepatic portosystemic shunt (TIPS). Patients with PH, caused by prehepatic portal vein occlusion, require recanalisation with stent or stent-graft often followed by additional TIPS. Stent-grafts used for TIPS, may occlude the outflow from the adjacent hepatic vein, potentially disturbing the circulation through the adjoining part of the liver.

In paper I, results of interventional treatment in children with PH, secondary to occlusion of the portal vein were reported. Intervventional treatment was feasible, but re-intervention and follow up were important for improvement of results. In paper IV, interventional radiological treatment in 24 patients with PH and occlusion of the splanchnic veins was evaluated retrospectively. In the majority of cases treatment was technically successful, with subsequent improvement of symptoms.

Paper II and III report results of experimental studies. Possible negative effects of hepatic vein occlusion by the stent-graft were evaluated with interventional, scintigraphic, radiopharmaceutical and histopathological methods. In the first experiment we found that arterial supply to the liver was diminished directly after hepatic vein occlusion. In the second experimental study, the outflow from the hepatic vein was evaluated directly after TIPS and re-evaluated after two weeks. Stent-grafts used for TIPS occlude the hepatic vein, but do not have prolonged circulatory effect and do not affect the liver parenchyma.

In conclusion, interventional treatment of patients with PH and occlusion of splanchnic veins is feasible and use of stent-grafts for TIPS has no long-lasting negative effect on the liver circulation.

Key words: portal vein occlusion, TIPS, portal hypertension, recanalisation, children, stent, hepatic vein occlusion, scintigraphy

Inger Keussen
To my family

Live as if you were to die tomorrow.
Learn as if you were to live forever.

Mahatma Gandhi
Contents

List of papers ................................................................................................................................. 9

Abbreviations ................................................................................................................................. 10

Introduction ............................................................................................................................................. 11

  Historical background ......................................................................................................................... 11
  Overview of the structure and the function of the liver ................................................................. 11
  Portal hypertension; etiology, causes and assessment ...................................................................... 12
  Portal hypertension; symptoms and treatment .............................................................................. 14
  TIPS .................................................................................................................................................. 17
  Recanalisation of splanchnic veins ................................................................................................. 22

Aims ......................................................................................................................................................... 24

Material and Methods ....................................................................................................................... 24

  Experimental studies ......................................................................................................................... 24
  Clinical studies ................................................................................................................................. 27

Results .................................................................................................................................................... 34

  Experimental studies ......................................................................................................................... 34
  Clinical studies .................................................................................................................................. 35

Discussion ............................................................................................................................................ 38
This thesis is based on the following published papers, which will be referred to in the text by their Roman numerals. The papers are appended at the end of the thesis.


Papers are reprinted with kind permission from Springer Science and Business Media and Georg Thieme Verlag KG.
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT</td>
<td>computerized tomography</td>
</tr>
<tr>
<td>ePTFE</td>
<td>expandable poly tetra fluoro ethylene</td>
</tr>
<tr>
<td>$^{99}$Tc$^{m}$–HSA</td>
<td>$^{99}$Tc$^{m}$labelled human serum albumin</td>
</tr>
<tr>
<td>HE</td>
<td>hepatic encephalopathy</td>
</tr>
<tr>
<td>IPVB</td>
<td>intra hepatic portal vein branches</td>
</tr>
<tr>
<td>IVC</td>
<td>inferior vena cava</td>
</tr>
<tr>
<td>MRA</td>
<td>magnetic resonance angiography</td>
</tr>
<tr>
<td>MR/MRI</td>
<td>magnetic resonance/magnetic resonance imaging</td>
</tr>
<tr>
<td>PH</td>
<td>portal hypertension</td>
</tr>
<tr>
<td>PV</td>
<td>portal vein</td>
</tr>
<tr>
<td>PVO</td>
<td>portal vein occlusion</td>
</tr>
<tr>
<td>ROI</td>
<td>region of interest</td>
</tr>
<tr>
<td>TIPS</td>
<td>transjugular intrahepatic portosystemic shunt</td>
</tr>
<tr>
<td>USG</td>
<td>ultrasonography</td>
</tr>
</tbody>
</table>
Introduction

Historical background

The ancient Egyptians had already associated liver disease with ascites which was documented in medical scripts from the middle ages (Henderson). A relationship between cirrhosis, varices and gastrointestinal bleeding was not identified until 1900. Ascites, cirrhosis and elevated portal pressure were linked together with the term portal hypertension, (PH), introduced by two French doctors, Gilbert and Villaret, 1906 (Henderson). At the beginning of the 20th century the “forward flow theory” still existed, assuming that portal hypertension resulted from an enlarged spleen rather than causing it. Different types of surgical treatment have been used for the management of portal hypertension such as shunts, splenectomy, omentopexy and oesophageal transection. The introduction of the liver transplantation in the 1980’s had an even greater impact on the management of portal hypertension (Carithers 2000). Proposed in 1969 by Rösch (Rösch et al. 1969), the first transjugular intrahepatic portosystemic shunt, (TIPS) was successfully created in patients at the beginning of the 1990’s. Using this less invasive, interventional radiological method, elevated portal pressure could be significantly decreased, with the resulting elimination of symptoms.

Overview of the structure and the function of the liver

The liver is the largest gland in the human body, with a weight of approximately 1500 g in a healthy adult. It is separated into the right and left lobes and further subdivided into segments. The most commonly used anatomical segmental classification was introduced by Couinaud. This classification divides the liver into eight independent segments, each of which has its own vascular supply, outflow and biliary drainage. The main cell type in the liver is the hepatocyte, which contributes to 80% of the liver volume and to 60% of the total cell population (Boyer et al. 2006). Most of the functions carried out by the liver, are accomplished by the hepatocytes, which extract and transform substances from the blood and has an exocrine and endocrine secretory function. The remaining cells consist of sinusoidal endothelial cells, perisinusoidal stellate cells and Kupffer cells. Hepatocytes are organized into plates or laminae and between these plates the hepatic sinusoids are located. A liver sinusoid is a small blood vessel, similar to a capillary, where oxygen-rich blood from the hepatic artery and the nutrient-rich blood from the portal vein are mixed. The sinusoids are highly permeable and are lined with discontinuous endothelium. The fenestrations of up to 2 µm in diameter, allow the passage of most macromolecules. The caliber of the sinusoids can increase more than ten times and is limited by the extracellular room, the space of Disse. The Kupffer cells, the immunocompetent component of the sinusoid wall, can take up and destroy foreign substances.

The liver has a dual blood supply through the portal and arterial systems, making the normal liver resistant to anoxia. The poorly oxygenated portal blood contributes to about 80% of the total blood supply to the liver. The remaining, approximately 20%, consists of well oxygenated blood from the hepatic artery. The PV gathers blood from the intestine, the pancreas, the spleen, the stomach and the gallbladder with contribution from the superior and inferior mesenteric veins, the splenic and gastric veins. Within the liver, the PV divides into two major branches, to the left and right liver lobe respectively. The portal venous system transports the nutrients from the gastrointestinal tract, as well as hormones, e.g. insulin and glucagon. These substances reach the liver in high concentrations and may be
Interventions for Portal Hypertension in Patients with Portal Vein Occlusion

metabolized here. The sinusoids have a vast cross-sectional area, creating a low transsinusoidal vessel resistance, pressure gradient and flow velocity. In order to cause an increase in portal pressure it has been calculated that 80% of the portal profile must be obliterated (Hulek et al. 2001), which is one of the most serious consequences of chronic liver disease. The drainage from the sinusoids is carried out by the hepatic veins. The main hepatic veins enter the inferior vena cava, IVC, just before it passes through the diaphragm.

### Portal hypertension; etiology, causes and assessment

At normal pressure the hepatic sinusoids maintain a flow of 1500ml/minute (Boyer et al. 2006), which increases after food intake. 5–10 mmHg is defined as normal portal venous pressure and PH is portal venous pressure exceeding 10 mmHg (1.3 kPa). However, these values are relative and depend on the pressure in the central venous circulation. It seems clear that varices do not de-

---

![Fig 1. Causes and sites of block for portal hypertension.](image_url)
velop when the porto-systemic pressure gradient is below 10 mmHg and variceal bleeding rarely occurs with a gradient below 12 mmHg (Vorobioff et al. 1996).

PH is classified into three groups, presinusoidal, sinusoidal and postsinusoidal (Fig 1).

Presinusoidal PH may be either extrahepatic or intrahepatic. The extra- or prehepatic obstruction is usually caused by thrombosis, malignancy, or stenosis following liver transplantation, whereas sepsis and hypercoagulability are less common causes. Among the intrahepatic reasons schistosomiasis, congenital hepatic fibrosis, sarcoidosis, malaria, primary biliary cirrhosis are described. World wide schistosomiasis is the main contributor of PH. In Europe and North America the sinusoidal cause of PH is associated with cirrhosis of the liver in more than 90% of the patients, mostly secondary to alcohol abuse. Other causes of PH are infectious and toxic hepatitis, primary liver fibrosis, hemochromatosis, Wilson’s disease, primary biliary cirrhosis and extrahepatic biliary obstruction. The main factor determining the clinical course, management and outcome for patients with PH is the status of the underlying liver disease.

The severity of liver disease is most often classified according to the MELD score and/or the Child-Pugh classification. The MELD (Model for end-stage liver disease) score is determined by three blood tests, bilirubin, prothrombin time (PT) measured as international normalized ratio (INR) and creatinine. The MELD score is calculated using the following equation:

\[
3.8 \times \log(e) \text{(bilirubin mg/dL)} + 11.2 \times \log(e) \text{(INR)} + 9.6 \log(e) \text{(creatinine mg/dL)}
\]

The score ranges from 6—40, where the lowest number indicates the least ill patient and the highest score the most severe condition. The MELD score is used for evaluation before TIPS, for patients on a transplant list, to gauge the mortality in patients with alcoholic hepatitis and also for assessment of a liver malignancy (Dunn et al. 2005; Montgomery et al. 2005).

For Child-Pugh classification see table 1. The most common causes of post hepatic obstruction are Budd-Chiari syndrome, stenosis of liver veins or IVC after liver transplantation, whereas veno-occlusive disease is an even rarer condition. The Budd-Chiari syndrome is an entity of diseases, characterized by a restriction of the hepatic vein outflow, mainly due to thrombotic occlusion of the hepatic veins. In veno-occlusive disease the IVC and liver veins are patent, but non-thrombotic obliteration is seen in the postsinusoidal liver venules, often affecting patients after bone marrow transplantation.

### Table 1. Child-Pugh classification: Grade A 5–6 points, Grade B 7–9 points, Grade C 10–15 points

<table>
<thead>
<tr>
<th>Parameter</th>
<th>1 point</th>
<th>2 points</th>
<th>3 points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bilirubin (μmol/l)</td>
<td>&lt;34</td>
<td>34–50</td>
<td>&gt;50</td>
</tr>
<tr>
<td>Albumin (g/l)</td>
<td>&gt;35</td>
<td>28–35</td>
<td>&lt;28</td>
</tr>
<tr>
<td>Prothrombin time(s) or INR</td>
<td>&lt;1.7</td>
<td>1.7–2.3</td>
<td>&gt;2.3</td>
</tr>
<tr>
<td>Ascites</td>
<td>None</td>
<td>Slight</td>
<td>Moderate</td>
</tr>
<tr>
<td>Encephalopathy</td>
<td>None</td>
<td>Minimal</td>
<td>Advanced</td>
</tr>
</tbody>
</table>
Increased resistance to portal venous flow in PH results in development of portosystemic collaterals and dilatation of the vessels in the splanchnic venous bed. Varices which develop from these collaterals and continue to enlarge carry an increased risk of bleeding. The blood from the splanchnic venous bed, drained directly into the systemic circulation through collaterals, bypasses the functional liver parenchyma. This has several negative consequences such as hormonal and metabolic imbalance, disturbed microbial filter mechanism, deterioration of the clearance of vasoactive substances, producing a hyperkinetic systemic circulation. Splanchnic vascular changes of vasodilatation and hyperemia occur and in parallel there is an increase in plasma volume. A hyperdynamic situation develops including high cardiac output, low total systemic vascular resistance and a low systemic blood pressure (Boyer et al. 2006).

Assessment of portal hypertension can be made by different methods. Results of clinical examination, laboratory tests, liver biopsy and radiological assessments contribute to diagnosis. Laboratory tests also give information about coagulopathy, renal and liver function, systemic infection, electrolytes and make assessment possible of the Child-Pugh and MELD scores. It is necessary to exclude occlusion of the portal vein or occlusion of its tributaries and branches, as well as the hepatic veins. The best methods are computerized tomography, CT, and magnetic resonance angiography, MRA, providing information about the anatomy and other associated findings as splenomegaly and developed collaterals. Ultrasonography, (USG), with Doppler is another method for visualisation of the portal and hepatic circulation, including information about presence, direction and character of the blood flow. Quantitative evaluation of flow velocity and flow volume in larger vessels can also be assessed. Contrast enhanced USG may sometimes provide additional information (Ueno et al. 2006, Venturi et al. 2007). Digital subtraction angiography is a traditional method for visualisation of the PV, either by transvenous or transarterial approach. Invasive methods also include carbon dioxide portography and direct transhepatic or transsplenic portography. Portal venous pressure can be measured by insertion of an end-hole catheter in a wedge position in a peripheral hepatic vein. A small amount of contrast is injected under fluoroscopic control to confirm correct position of the catheter. The measurement is repeated in several veins and the highest pressure is recorded. The pressure in the IVC or in the right atrium is subtracted from the wedged hepatic venous pressure and the difference represents the gradient (Boyer et al. 2006). Another method, also available for patients with hepatic vein thrombosis, is the direct transhepatic puncture of the portal veins. Although, most of the portal pressure measurements are obtained during the TIPS procedure.

Portal hypertension; symptoms and treatment

Ascites and encephalopathy are the two clinical manifestations indicating decompensation. In contrast bleeding from varices, hypersplenism and splenomegaly may be indicators of compensated disease and has a worse prognosis (Henderson).

Ascites

Ascites is the result of a shift in the balance between production and resorption of free fluid in the peritoneal space. The fluid, rich in protein, is filtered to the extra cellular space in the sinusoids, but not in a sufficient way when PH is present. Sinusoidal hypertension alone is not enough to create ascites, which also requires plasma volume expansion, sodium retention and the activation of neurohumeral systems amongst others. In cirrhotic patients
about 10% will develop refractory ascites, defined as not responding to high doses of diuretics (Boyer et al. 2006). The prognosis for a patient with refractory ascites is poor, about 50% will die within a year.

**Hepatic encephalopathy**

Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome that accompanies severe liver disorder or is due to a significant shunting between portal and systemic circulation, thus seen both after placement of a surgical porto-systemic shunt as well as in TIPS creation. Acute HE is associated with fulminant hepatic failure which can result in hepatic coma and death. Chronic HE in PH, is due to insufficient detoxification function of the liver with toxic products by-passing the liver and entering the systemic circulation. The toxins include nitrogenous products from the gut. Clinically chronic HE may be difficult to diagnose and is often reversible. It can be revealed by neuropsychological tests and MR spectroscopy (Grover et al. 2006). In the clinically manifest form confusion, agitation and other psychiatric disturbances are present (Hulek et al. 2001). Potential factors contributing to post shunt encephalopathy, include loss of prograde portal perfusion and loss of venous hypertension with increased ammonia absorption (Somberg et al. 1995).

**Hydrothorax**

Hydrothorax is a common finding in a patient with PH, but there is poor correlation between the portal venous pressure and the size of the spleen. Splenomegaly may be associated with hypersplenism. In numerous cases leucopenia, thrombocytopenia and anaemia are present, which can cause clinical problems such as bleeding and infection.

**Varices**

The portal circulation has an extensive collateral system, which may be activated when an increase in pressure occurs. The ma-
Major sites for collateral pathways are gastro-oesophageal, haemorrhoidal, periumbilical and retroperitoneal. The gastric and oesophageal collaterals cause the major clinical problems and are often revealed at endoscopy at an early stage. Variceal bleeding is a medical emergency, which carries a mortality rate of 30%, where most deaths are found in the group with a Child-Pugh score ≥ 8 points (deFranchis 2005). Re-bleeding in the first 7–10 days after the first bleed is a poor prognostic sign. However, only 30% of patients with cirrhosis have oesophageal varices and only 30% of these will bleed from them (Collini et al. 1990). Most haemorrhages occur within two years from diagnosis which is usually made by endoscopy (Boyer et al. 2006).

Valves are present in the perforating veins of the oesophagus, but they become insufficient in some patients with PH, leading to an increase in variceal size. The oesophageal varices are classified in 4 grades. The low risk varices, grade 1, are small-sized, easy to compress by the endoscope and seldom revert spontaneously. The most severe varices, grade 4, have red spots developed on the surface, have weakened wall and rupture easily (Hulek et al. 2001). Similar classification is used for gastric varices. The umbilical vein may open and drain the portal blood towards the abdominal wall creating “caput meduseae”—a network of enlarged subcutaneous veins around the umbilicus. Other large venous shunts may be found at other places in the upper abdomen, like spleno-renal shunts, which are occasionally as large as the surgically created shunts (Boyer et al. 2006).

Another well-known complication from PH is bleeding from rectal, colonic, jejunal and duodenal varices (Vidal et al. 2005). Porto systemic venous collaterals can also develop around the stoma from a colostomy or ileostomy. Enlargement of these may result in development of stoma varices, which sometimes require interventional treatment (Nayar et al. 2006).

**Treatment**

Management of PH is based on different types of treatment which include; therapy of the underlying liver disease, pharmacological treatment, balloon tamponade, endoscopic, interventional and surgical procedures. Today the surgical procedures have been replaced to a large extent by TIPS. Termination of alcohol abuse, anitviral and pharmacological therapy including beta-blockers, vasodilatators, vasoconstrictors and somatostatin, may be helpful in the early stages of the disease. Antibiotics are given to prevent bacterial complications and lactulose to prevent HE. Temporary arrest of acute bleeding can be established with a double lumen balloon, Sengstaken tube, which can be left in place for 24 hours. Two different types of endoscopic therapy are available. Sclerotherapy includes use of thrombotic agents, injected directly into the varix or in its proximity, creating fibrosis in the mucosa overlying a varix. Variceal banding is a different approach, where the varix is sucked into an applicator and a strangulating rubber band is applied. Both these methods are used primarily in the treatment of bleeding oesophageal varices but are more difficult to apply in cases of bleeding from gastric varices. Endoscopic ligation has been reported to be superior to combined ligation and sclerotherapy (Saeed et al. 1997). Coagulopathy and hepatic failure may also be present, complicating the management of the patient.

For long-term management of PH, surgery was previously a method to be considered in patients not responding to conventional therapy and has been in clinically use since 1940’s. These surgical options include portocaval shunts, mesocaval, mesorenal or mesoaatrial shunts, gastric devascularisation procedures, oesophageal devascularisation, distal splenorenal shunts and Rex shunts, in which the superior mesenteric vein is linked to the left portal vein (Bambini et al. 2000; Dasgupta et al. 2006; Kim et al. 2005; Shaked et
The incidence of post shunt encephalopathy is unknown but has been reported to be around 10–50% (Rikkers et al. 1992). The shunts can be divided into total and selective shunts. The total shunts decompress both the portal and variceal venous system. In contrast the selective shunts only decompress the variceal system, leaving the portal flow unchanged. The incidence of HE after selective shunts was reported significantly lower than after total shunts (Galambos et al. 1976). Direct gastric and oesophageal devascularization procedures have almost ceased completely in clinical practise. Bleeding from stoma varices can be treated by embolisation with coils and/or sclerosing agents, after superselective catheterisation, with or without TIPS.

Some patients with intrinsic liver disease can only be treated by liver transplantation, which represents the definite therapy. This revolutionary method has altered the prognosis, especially in patients with severe liver disease (Child-Pugh class C). After experimental studies in the 1950’s the first liver transplantation in man was performed 1963. The initial results were poor, but with medical anti-rejection treatment improvements and better organ preservation the results improved substantially. 5 year survival rate is now close to 80% in patients with non-malignant disease (Björnsson et al. 2005). Globally the most common indication is chronic hepatitis C and alcohol cirrhosis. In the Nordic countries the most common reason for transplantation is primary sclerosing cholangitis but the amount of patients with hepatitis C is increasing. The survival rate is lower for patients with previous alcohol liver disease. PVO has previously been considered a contraindication for orthotopic liver transplantation, but in the last 15 years surgical vascular technique has been successfully developed (Yan et al. 2003). Thus PVO no longer remains an absolute contraindication for transplantation but represents a higher surgical risk (Shaked et al. 1991) and extension of thrombus into the remaining splanchnic vessels can result in grafts failure (Senzolo et al. 2006).

**TIPS**

The TIPS technique was first proposed by Rösch (Rösch et al. 1969). A transjugular approach to the portal system was found by an inadvertent puncture, during clinical attempts to enter the biliary system. Rösch realized that patients with severe PH were in a bad condition, were a poor surgical risk and could benefit from a procedure lowering the portal pressure. TIPS in dogs, in the initial experiments, had short patency, since the parenchymal tract recoiled almost immediately, closing the connection between the portal and systemic circulation. The introduction of modern angioplasty catheters in 1970’s made it possible to improve the patency, but even so the results were not convincing in the beginning.

In 1982 the first clinical TIPS was performed by Colapinto (Colapinto et al. 1982). A shunt was created using a 9 mm balloon inflated for 12 hours, which accomplished considerable decrease in the portal pressure. The long term results were, however, still not satisfactory. The use of metallic stents stabilizing the TIPS channel, improved the long term patency of the shunt. Palmaz reported in 1985 that TIPS created with balloon expandable stents in dogs with PH, had prolonged patency in comparison to previous experiments (Palmaz et al. 1985). At autopsy the stents were covered by a thin layer of pseudointima, 1.0–1.5 mm thick and completely endotheialised. In 1988 Richter performed the first clinical TIPS with stents, reported in 1990 (Richter et al. 1990). They created a shunt, dilated to 9 mm diameter and stabilized with two Palmaz stents placed coaxially. The patient’s portal pressure decreased from 38 to 18 mm Hg and the clinical condition improved significantly. The technique was thereafter refined, adopted by interventional radiologists and documented in large studies.
Indications and contraindications for TIPS

The main indication for a TIPS shunt is bleeding, which is uncontrolled by pharmacological and/or endoscopic therapy. TIPS can be performed in both an emergency situation, as well as in an elective procedure in patients with repeated bleeding episodes (Boyer et al. 2005; Bilbao et al. 2002). The criteria and definitions regarding bleeding episodes are stated in the Baveno IV consensus workshop (deFranchis 2005).

All indications and contraindications are summarized in Table 2 and 3 (Boyer et al. 2005).

Since every TIPS procedure is assessed due the patient’s clinical status, a malignant or cystic liver disease may not be a contraindication in an emergency situation.

Preprocedural assessments

The portal venous anatomy should be evaluated either by CT or MRA. These modalities will also reveal large collaterals, splenomegaly, ascites, size, structure and possible focal lesions of the liver. Any venous disturbances, as well as spatial abnormalities, will be exposed. USG with Doppler and possible contrast enhancement, verifies patency of the portal vein and may add information about the collaterals and of the flow directions and velocities. Laboratory tests give information about coagulopathy, renal and liver function, systemic infection, electrolytes and make assessments possible of the Child-Pugh and MELD scores. If applicable, improvement of the patient’s clinical status is accomplished, such as correction of pathological coagulation and/or electrolyte status, drainage of ascites and/or hepatic pleural effusion (Roussos et al. 2007). Prophylactic broad spectrum antibiotics are given on the day of the procedure and continued for at least two more days. Favourable prognostic factors for TIPS are age less than 60 years, female gender, preserved liver function (Bilirubin < 50 micromol/l), absence of chronic HE, preserved renal function and serum sodium (>125 mmol/l) (Hulek et al. 2001). Montgomery et al. have reported that elective patients with MELD score > 24 should not be endorsed for TIPS procedures (Montgomery et al. 2005).

Table 2. Indications for TIPS placement

<table>
<thead>
<tr>
<th>Efficacy determined by controlled trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>– Secondary prevention variceal bleeding</td>
</tr>
<tr>
<td>– Refractory cirrhotic ascites</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Efficacy assessed in uncontrolled series</th>
</tr>
</thead>
<tbody>
<tr>
<td>– Refractory acutely bleeding varices</td>
</tr>
<tr>
<td>– Bleeding gastric varices</td>
</tr>
<tr>
<td>– Portal hypertensive gastropathy</td>
</tr>
<tr>
<td>– Gastric antral vascular ectasia</td>
</tr>
<tr>
<td>– Refractory hepatic hydrothorax</td>
</tr>
<tr>
<td>– Hepatorenal syndrome (Type 1 or type 2)</td>
</tr>
<tr>
<td>– Budd-Chiari syndrome</td>
</tr>
<tr>
<td>– Venous-occlusive disease</td>
</tr>
<tr>
<td>– Hepatopulmonary syndrome</td>
</tr>
</tbody>
</table>

Table 3. Contraindications to TIPS placement

<table>
<thead>
<tr>
<th>Absolute</th>
</tr>
</thead>
<tbody>
<tr>
<td>– Primary prevention of variceal bleeding</td>
</tr>
<tr>
<td>– Congestive heart failure</td>
</tr>
<tr>
<td>– Multiple hepatic cysts</td>
</tr>
<tr>
<td>– Uncontrolled systemic infection or sepsis</td>
</tr>
<tr>
<td>– Unrelieved biliary obstruction</td>
</tr>
<tr>
<td>– Severe pulmonary hypertension</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Relative</th>
</tr>
</thead>
<tbody>
<tr>
<td>– Hepatoma, especially if central</td>
</tr>
<tr>
<td>– Obstruction of all hepatic veins</td>
</tr>
<tr>
<td>– Portal vein thrombosis</td>
</tr>
<tr>
<td>– Severe coagulopathy (INR &gt;5)</td>
</tr>
<tr>
<td>– Thrombocytopenia (&lt;20,000/cm3)</td>
</tr>
<tr>
<td>– Moderate pulmonary hypertension</td>
</tr>
</tbody>
</table>
**TIPS technique**

The TIPS procedure is performed with the patient in full anaesthesia, but may be done under conscious sedation with local anaesthesia. Access to the internal jugular vein, on either the right or left side, is established through visualisation of the vein in the neck by ultrasound. After administration of local anaesthetic, vein puncture is performed and a guide-wire and a catheter are inserted into the superior vena cava, passing the right atrium into the IVC. An angulated catheter is used to enter a hepatic vein, usually the right, and the tip is advanced distally. The correct position is verified with contrast injection and thereafter a 10 Fr sheath is advanced over a stiff guide wire. Subsequently, access to the PV is established from the hepatic vein. Since the viscosity of the carbon dioxide is 400 times lower than that of liquid contrast media, the gas, injected through the catheter in wedged position in the hepatic vein, can pass the sinusoids in an amount large enough to visualize the portal venous tree. This can provide necessary information for successful puncture, thus reduce the risk of complications. The access may be performed either by blind puncture, based on anatomical information from CT or MRI, or on previous carbon dioxide portography. Puncture can also be facilitated by simultaneously performed USG. After the puncture contrast injection confirms correct position in the PV. An optimal parenchymal tract should be created within 1 cm from the confluence of the hepatic vein and the IVC, entering a right portal vein branch 1–2 cm peripherally to the portal bifurcation. Measurements of the pressure in the right atrium, hepatic vein and in the PV are recorded. The highest resistance to the dilatation of the channel is found in the entrances of the hepatic and portal veins. The shunt device, a stent or a stent-graft (8–10 mm) is chosen, according to the patient’s clinical state, porto-systemic pressure gradient, age, existing HE and indication. The stent-graft should cover the entire intrahepatic tract and the hepatic vein, to minimize the risk of stenosis. The placement is confirmed by contrast injection and any irregularity in the shunt can be corrected by balloon dilatation. Following repeated pressure measurements and portography, the procedure is terminated.

**Stent and stent-graft selection**

The initial trials with stents to maintain patency in a TIPS were performed with balloon expandable metallic stents. This type of stent is a stainless steal tube, expanding to the desired size determined by the size of the inflated balloon. The final stent diameter can be chosen according to the porto-systemic gradient. A Wallstent, a self-expanding bare stent, was and probably still is, the most commonly used stent for TIPS creation. It is also made of stainless steal, has great flexibility, but undesired shortening may create problems with accurate placement. Also dacron-covered Wallstents, Wallgrafts have been used, but with poor results (Haskal et al. 1999). Self-expanding nitinol stents have also been used, but more seldom due to difficulties with removal in the case of liver transplantation (Cla- vien et al. 1998) and possible fracture of the stent (Robertson et al. 2007). Since 2000 a self-expanding stent-graft, especially designed for TIPS, Viatorr, has been in commercial use (Rose et al. 2001). This stent-graft, has a nitinol stent skeleton and is covered by polytetrafluoroethylene,(PTFE) graft. This device has two different functional segments. The cranial, main portion, consists of the graft-lined segment (4, 5, 6, 7 or 8 cm), outlining the intrahepatic tract, extending into the hepatic vein up to the IVC. The minor part of the stent-graft is bare, two cm long and is positioned in the PV. A circumferential radio opaque gold marker indicates the beginning of the graft covered portion of the stent. An additional gold marker is located in the graft
covered cephalic end. The Viatorr is available in diameter of 8, 10 or 12 mm.

This stent-graft has no foreshortening and the correct length of the device can be easily chosen. If a bare stent is used for TIPS, the flow from the hepatic vein into the IVC is unhindered but if a stent-graft is used, the outflow from the hepatic vein is blocked. The effects of such an occlusion were not known. Therefore use of a stent-graft could be contraindicated in a patient with already deteriorated liver function. Study of this problem was the aim of our animal experiments.

**Complications of TIPS procedures**

Complications can be divided into procedural and post procedural. Bleeding is the most serious of the major complications but occurs in less than 2%, with a procedural and post procedural mortality rate of 1 and 3% respectively, reported in the early days of TIPS procedures (Rössle et al. 1996). Haemorrhage may occur from perforation of the liver capsule, from the puncture site outside the liver and rarely from perforation of the right atrium (Terrrini et al. 2007). Multi organ failure, ARDS (adult respiratory distress syndrome), severe sepsis, renal or hepatic failure are reported, with a higher incidence in unfavourable MELD or Child-Pugh scores. Minor complications include small intraperitoneal haemorrhage, puncture of bile ducts, arteries, gallbladder or right kidney. Also transient decrease in liver function, sepsis, haemolysis, pancreatitis and encephalopathy are described. Thrombosis of the TIPS usually occurs early and can happen within 24 hours of TIPS creation (Boyer et al. 2005). Use of anticoagulation has not improved long-term patency of the shunt (Shiffman 1996).

The most frequent post procedural complications are shunt dysfunction and HE. Shunt dysfunction may be secondary to pseudointimal hyperplasia, which consists of formation of connective tissue, mesenchymal cells, endothelial cells and fibroblasts. Macrophages may also be present (Haskal et al. 1999). This results in stenosis of the channel, with recurrence of PH and thereby related symptoms,
and the complication has been a limiting factor for the use of bare stents in TIPS. The frequency is reported to vary from 18–78% and the shunt dysfunction should be reduced by the use of covered stents (Boyer et al. 2005). Another limiting factor for long time patency is the true intimal hyperplasia in the drained hepatic vein, creating stenosis, which requires reintervention. In the intimal hyperplasia proliferation of endothelial cells is seen. This problem is mostly observed in TIPS created with bare stents. Dilatation with a balloon catheter is the first treatment option. In cases of persistent stenosis, additional stent placement is performed.

**Longterm results**

TIPS and endoscopic treatment have been compared in several studies, demonstrating a significant reduction of re-bleedings with TIPS, to the price of more HE without any improvement on survival rates (Papatheodoridis et al. 1999; Burroughs et al. 2002). The same results were found for surgical shunts. More recent studies conclude, however, that TIPS is more effective and show a tendency to improve survival rates (Rössle et al. 2004).

The permanent shunting of portal blood away from the liver may increase the risks of liver failure and HE. The initial TIPS created with bare stents, had a high failure rate due to shunt dysfunction, which required repeated radiological interventions. Since the introduction of Viatorr, the pseudointimal hyperplasia formation has been reduced (Rössle et al. 2006), reported also in a randomized study (Bureau et al. 2007). In a long-term retrospective study (Rössle et al. 2006) the shunt patency in 100 patients implanted with Viatorr, was evaluated and the two year patency rate was reported to be 74–76 %. The chosen diameter for the stent-graft can thereby be smaller, which reduces the incidence of HE. HE is a serious complication, where the reports on frequency have been conflicting in the literature. Somberg et al. report rates of 10-50% of all TIPS procedures (Somberg et al.1995). De novo or deterioration of a preexisting HE is seen in 20–41% of cases (Huoncker et al. 1999; Somberg et al.1995). Studies have demonstrated an increase in HE after TIPS, when pressure gradient < 12 mm Hg. It has therefore been suggested that the aim of the individual reduction should be about 40–50% of the baseline (Rössle et al. 2001). If liver function or HE deteriorates progressively an arterio-portal fistula should be excluded. It results in reduced arterial blood supply, which may place the patient in a critical situation. An immediate occlusion or shunt reduction is necessary. Directly after the shunt is opened the systemic pressure and the cardiac output increase about 30% accompanied by a further reduction in the low vascular resistance. These changes return towards baseline levels after a few hours, with a 10% residual change (Huoncker et al. 1999).

The development or worsening of preexisting HE has been described in 20–31% (Somberg et al. 1995). Unfavourable factors for the development of HE include high age, advanced liver disease, previous encephalopathy and large shunt diameter. “De novo” encephalopathy after TIPS placement is most likely to respond to treatment with lactulose and/or neomycin. If the patient develops refractory HE, either the TIPS diameter can be reduced or the shunt can be occluded, in order to improve the symptoms. The incidence of HE after surgical procedures has been reported to range from 20–50%, usually with lower frequency in small-diameter shunts and in with Child-Pugh A and B patients (Somberg et al. 1995).

Another possible disadvantage of TIPS may be circulatory disturbances in the liver, not to neglect since these patients already have an impaired liver function. A stent-graft used in a TIPS blocks the drainage from the liver vein into the IVC and circulatory effects have been noted (Bureau et al. 2002; Walser et al.
Interventions for Portal Hypertension in Patients with Portal Vein Occlusion

2000). This has not been fully investigated and was the focus of our experimental studies (Paper II and III).

TIPS in children

Even if TIPS procedures in adults are relatively common, the experiences of TIPS in children are limited. The technical success rate is lower than in adults, 75–90% vs 95% in adults (Fasulakis et al. 2006). The smaller size of the venous structures, the smaller liver and the presence of anatomical variants are limiting factors in paediatric cases. The small amounts of contrast medium which can be used, can also be a limiting factor. Modification of the usual technique in TIPS may be needed in children for technical success.

Recanalisation of splanchnic veins

Portal vein occlusion, PVO, is a rare condition, which predominantly occurs in cirrhotic patients (Van Ha et al. 2006) and may be secondary to hypercoagulopathy, inflammatory processes, malignancies and mechanical manipulation of the PV (Vivas et al. 2000). PVO can be intra- or extra hepatic and acute or chronic. Anatomically PVO can be classified into categories depending on how much of the vein and its tributaries that are involved, which may have a prognostic relevance. Patients with thrombus involvement of the mesenteric vasculature carry a higher risk of bowel infarction and a lower risk of variceal bleeding, than those with isolated PVO (Webster et al. 2005). Symptoms may be diffuse and should be considered in patients with unspecific abdominal pain, in cases of deterioration in patients with known liver disease or if signs of PH are present in patients without simultaneous liver disease. In children the most common cause is infection, mostly originating from umbilical vein catheterisation. PVO may be associated with growth retardation in children (Bellomo-Brandão et al. 2003). In the chronic form porto-portal or porto-systemic collaterals are developed and/or cavernous transformation (periportal collaterals) can be detected. The first symptom may be gastrointestinal bleeding but in many cases very few symptoms are present or may be absent altogether. In some patients, abdominal pain, fever, nausea and signs of mechanical bowel obstruction or ascites are found. Benign stenosis of the PV is a known complication of liver transplantation and is commonly found at the site of the anastomosis. Spontaneous recanalisation of PVO, is very rare and treatment options for symptomatic patients are pharmacological therapy, splenectomy and surgical shunts. Endoscopic treatment may be useful in patients with variceal bleeding. Benign stenosis are in most cases, responding to balloon dilatation.

Surgical shunting has previously been indicated in rare cases, where bleeding cannot be controlled by medical means, although earlier reports suggested high mortality and morbidity rates (Webb et al. 1979). In children the surgical complications include HE, rebleeding, shunt occlusion and technical difficulties due to small vessel size (Senyüz et al. 2001). The selection of shunting procedures for PVO, total or selective, has been a matter of debate (Mosiman et al. 1990). It has been suggested that children with PVO may have subtle deficiencies in liver function and that chronic diversion of portal flow from the liver may lead to progressive liver dysfunction (Bambini et al. 2000). The distal splenorenal shunt (Warren shunt) has been advocated for the treatment of children with severe hypersplenism secondary to the PVO. Restoration of portal flow to the liver by bypassing the PVO, normalizes the portal venous pressure and successfully decompresses the spleen which inhibits consumption of platelets and leucocytes (Shilyanski et al. 1999). In patients with patent IPVB the Rex shunt restores normal hepatopetal physiological flow, prevents
HE and has been used for patients with extra hepatic PH. This shunt uses an autologous vein graft, classically the left internal jugular vein, and extends from the mesenteric vein to the left branch of the portal vein (Bambini et al. 2000). The Rex shunt was originally reported as a method of treating PV thrombosis after liver transplantation (Audet et al. 2002). Late shunt stenosis and technical difficulties in patients with liver transplants have been reported after Rex shunt surgery (Bambini et al. 2000). Reconstructive surgery may be technically challenging or impossible due to non-availability of suitable vessels. Longstanding PVO may cause liver cirrhosis and if the IPVB are occluded transplantation of the liver is the necessary treatment. However, vein-grafts used for liver transplantation has limited long-term patency (Sugawara et al. 2006). The incidence of PV thrombosis in patients being considered for transplantation varies between 5 and 15%. The most widely used techniques are surgical thrombectomy and shunting with a venous graft. Portal thrombosis recurrence rates may be as high as 30% (Charco et al. 2005). PVO is not an absolute contraindication for liver transplantation but extension of thrombus into the remaining splanchnic vessels can severely reduce the inflow from the splanchnic veins and result in a graft failure (Shaked et al. 1991).

Development of interventional radiological tools and methods made attempts possible to recanalise occluded veins. Interventional treatment of PVO was previously reported only in few cases. Paper I and table7 summarizes results of treatment of patients with PVO.
Interventions for Portal Hypertension in Patients with Portal Vein Occlusion

Aims

The purpose of this thesis was to evaluate interventional treatment in patients with portal hypertension and occlusion of the portal vein and further to evaluate if stent-graft used for TIPS had any negative effects on hepatic circulation.

The specific aims were:

- To evaluate possibilities for interventional treatment in children with portal vein occlusion (Paper I).

- To evaluate if changes in hepatic circulation, following placement of stent-grafts used for TIPS, which occlude the hepatic vein, had negative consequences for the liver circulation (Paper II and III).

- To evaluate results of interventional treatment in patients with portal hypertension and occlusion of the splanchnic veins (Paper IV).

Material and Methods

Experimental studies

Paper II and III report results of experimental studies. Possible negative effects of hepatic vein occlusion by the stent-graft were evaluated with interventional, scintigraphic, radiopharmaceutical and histopathological methods. All experiments were performed after approval by the Animal Ethics Committee of Lund University.

Animals

14 healthy, domestic pigs were used in the experiments. In the first study (paper II) their body weight were approximately 20 kg and in the second study (paper III) approximately 36–40 kg. In the second study the animals were transferred to and kept in the animal care facilities for two weeks, when the second part of the experiments were performed. All animals were fed with regular food without any dietary restrictions. All procedures were performed under general anaesthesia, induced by intramuscular injection of 2 mg/kg azaperone (Stresnil Vet, Leo, Helsingborg, Sweden) followed by intravenous injection of 2–4 ml thiopental 5% solution (Sodium Pentothal, Abbott Laboratories, N.Chicago, IL, USA). After intubation, anaesthesia was maintained by artificial ventilation with a mixture of oxygen and nitric oxide and continuous infusion of ketamin-hydrochloride (Ketalar, Parke-Davis, Solna, Sweden) 1 mg/min and midazolam (Dormicum, Roche, Stockholm, Sweden) 5 mg/hour. At the end of the experiments, all animals were sacrificed by an intracardial injection of an overdose of potassium.

Interventional methods

All procedures were performed in experimental animal facilities. The diagnostic, interventional and TIPS procedures were performed on the angiography table (paper II and III) and the pigs were transported to the gamma camera for the scintigraphic examinations (paper II). After surgical cut-down, the left jugular vein was catheterized. A 5 Fr Cobra catheter was inserted into the superior vena cava and advanced via the IVC into the right hepatic vein. Contrast injection verified correct position in a peripheral branch and the tip of the catheter was used as a target for the percutaneous puncture to follow. The puncture, performed with a 0.9 mm needle, was replaced over a 0.018 inch guide wire, to a 5 Fr cannula. Free outflow from the right hepatic vein was checked by contrast injection. The technique for creating a TIPS was similar in both studies and identical to the technique in humans (Richter et al. 1990). For transhepatic PV access, the PV was punctured blindly, from the right hepatic vein.
Paper II

Through a cut-down, a 7 Fr introducer sheath was placed in the right femoral artery. Using angiographic technique a 4 Fr catheter was advanced into the gastroduodenal artery, which was embolised with pieces of Gelfoam and thereby excluded from any involvement in the assessment. The tip of the catheter was thereafter placed in the common hepatic artery. Information about the anatomy was obtained by hepatic angiography. Scintigraphic examination followed by injection of $^{99}$Tc$^{m}$ labelled human serum albumin ($^{99}$Tc$^{m}$ –HSA) through the catheter remaining in the common hepatic artery. For a pilot study performed in one pig, a 10 mm occlusion balloon catheter, inserted by a transjugular route, into the right hepatic vein was used. Scintigraphic examinations were performed with an inflated respectively non-inflated balloon, to determine if possible changes in the arterial supply to the liver were measurable.

Following transhepatic puncture, predilatation of the TIPS channel was performed with an 8 mm balloon, followed by insertion of an 8x40 mm stent. A new $^{99}$Tc$^{m}$–HSA injection was performed, after the post TIPS portography. Subsequently a 12x40 mm stent-graft was inserted in the cranial part of the shunt and dilated with a 10 mm balloon. (Fig 4) The hepatic vein occlusion was confirmed by contrast injection through the transhepatic cannula (Fig 5). Repetition of the scintigraphic examination was performed.

Scintigraphic methods

In our study we used $^{99}$Tc$^{m}$ labelled human serum albumin ($^{99}$Tc$^{m}$ –HSA) (Mallinckrodt Medical B.V., Petten, Holland), a substance frequently used for circulation and blood flow studies (Goins et al. 1996; Mallinckrodt 1995). Changes in the arterial blood flow were evaluated with scintigraphic methods.

Before TIPS was created, 40 MBq of $^{99}$Tc$^{m}$ –HSA was injected in the common hepatic artery. For the second (after stent placement) and third (after stent-graft placement) assessments, the injected isotope doses were

Fig 4. Blood flow through the TIPS channel.

Fig 5. Percutaneous contrast injection in the right hepatic vein. Outflow is blocked by the stent-graft.
increased three-fold to 120 and 360 MBq of $^{99m}$Tc-HSA, in order to minimize the necessary background subtraction. With the pig in supine position planar static images were obtained in anterior and posterior projections with a double head camera. The background activity was subtracted in anterior and posterior scans immediately before the second and third studies. A region of interest, ROI, was defined for each pig, to be the region of the liver drained by the right liver vein, which was blocked by the stent-graft. The ROI was determined according to the angiographic and venographic examinations, obtained before creation of TIPS. Due to anatomic variations the ROI was somewhat different for each pig. This area was used for measurements of the changes in the arterial blood flow, assessed by scintigraphy. For statistical evaluation of the results, Friedman’s test was used for comparing the activities before TIPS, after stent and after stent-graft placement, respectively. Provided an overall significant difference was detected, Wilcoxon’s signed-rank test was used for further comparisons.

Paper III
After transjugular insertion of a catheter in the right hepatic vein, a percutaneous transhepatic puncture of this vein was performed. A subcutaneous reservoir, a port-a-cath, was implanted subcutaneously, lateral to the liver, with the tip positioned in the right hepatic vein, approximately five mm from the confluence into the IVC. This reservoir was intended to be used for repeated radionuclide injections for the entire study. An access to the portal system was then created, using the previously described technique, by a transjugular route. Subsequently the radionuclide was injected through the port-a-cath, into the right hepatic vein. Blood samples were obtained after 1, 3, 5 and 10 minutes from a peripheral vein in the left ear. Then TIPS was created with a 10x40 mm stent-graft (Viatorr,
Endoproteosis, GORE®, Flagstaff, AZ, USA) and dilated with a 10x40 mm balloon after the placement. Portography confirmed free flow through the shunt (Fig 6). Contrast injection through the port-a-cath verified occlusion of the outflow from the hepatic vein by the stent-graft (Fig 7). Injection of radionuclide in the occluded hepatic vein through the port-a-cath was performed, followed by peripheral blood samplings at the intervals described above.

Revised study was implemented after two weeks. Unfortunately all the port-a-caths had dislodged from their locations in the hepatic veins and were found in the peritoneal space. Therefore transhepatic puncture of the right hepatic vein was performed under fluoroscopic control, towards the cephalic portion of the stent-graft. Contrast injection demonstrated the correct position of the needle tip in the vein. The $^{99m}$Tc–HSA was injected in the hepatic vein and sampled from a peripheral vein at the same intervals, 1, 3, 5 and 10 minutes after the injection.

**Radiopharmaceutical methods**

In our study we used Techne Scan® HSA (Mallinckrodt Medical B.V., Petten, Holland) which was labelled with $^{99m}$Tc according to the manufacturer’s instructions (Mallinckrodt). After 15 minutes incubation time the preparation was ready for use. The amount of free pertechnetate varied between 0.04% and 0.45% (mean 0.25%). Blood samples were weighed and measured for activity in a gamma counter. The percentage of the injected radioactivity leakage to the peripheral blood was calculated, assuming that the blood volume of the pig consisted of 8% of the total body weight.

**Histological methods**

After the animals were killed, the livers were removed en bloc and three different specimens from each of the livers were sent for histopathological examination. One sample was obtained from the part of the right liver lobe drained by the occluded liver vein, one sample from the left liver lobe and the third sample was including the stent-graft. The tissues were fixed in 10% natural buffer formalin and embedded in paraffin. Slides were prepared and stained with hematoxylin and eosin according to the standard protocols.

**Clinical studies**

**Paper I**

**Patients**

Five children, 8–14 years old, four boys and one girl, were treated. All children had symptoms from PH, due to PVO. In three of the children, the PVO was caused by neonatal catheterization of the umbilical vein. In the remaining two children infection and coagulation disorder were the reasons. All children had 1–5 bleeding episodes from oesophageal varices. Thrombocytopenia, with platelet counts of 24–53 secondary to splenomegaly, was also seen in all children. Two of the children required repeated endoscopic sclerotherapy, whereas the other three only received pharmacological treatment.

**Methods**

All children were examined before the interventional procedures with Doppler USG and CT or MRI. All the patients were treated in the angiography suite under general anesthesia. Blood pressure in the systemic and portal circulation was checked repeatedly. Recanalisation of the occluded part of the PV was intended in all patients. In one child, the recanalisation was performed three months after partial embolisation of the spleen for safety reasons. This child’s parents banned possible blood transfusion for religious reasons. Partial embolisation of the spleen was performed in four children. In these children a selective angiography of the splenic artery...
was performed to obtain anatomic information and to plan the embolisation. A 5 Fr Cobra catheter was thereafter inserted into the splenic artery from a femoral approach, followed by super selective catheterisation of the intrasplenic branches with a 3 Fr co-axial microcatheter. The embolisation of the 50–70% caudal portion of the spleen was intended. A mixture of polyvinyl alcohol particles 250–355 µm, 1 g benzylpenicillin, 80 mg garamycin, 5 ml NaCl solution and 10 ml contrast medium (Omnipaque 300 mg I/ml) was used for the embolisation. Under fluoroscopic control the mixture was injected until the flow ceased in the embolised branches. The result was checked directly after embolisation with contrast injection and with CT of the upper abdomen after 3–7 days. The IPVB were punctured by common TIPS technique (Richer et al. 1990), either from the right or the middle hepatic vein, by paediatric or adult TIPS set. Percutaneous transhepatic puncture of the IPVB was achieved with a 15 cm long 0.9 mm needle. Puncture was performed under biplane fluoroscopy with the needle slowly withdrawn under simultaneous, gentle injection of contrast medium, until the tip was in the IPVB. The needle was thereafter replaced over a 0.018 Cope mandrill wire (William Cook, Europe, Bjaeverskov, Denmark), by a 5 Fr catheter and portography was accomplished by contrast injection. Transsplenic puncture was always performed after arterioportal embolisation, below the costal arch in order to minimize the movements of the needle due to respiration. If necessary the access to the splenic or portal vein was reinforced by a 5 or 7 Fr introducer sheath. Recanalisation of occluded PV was attempted using glide wires and different angiographic catheters. Palmaz stents, Jomed stent graft and a Wallstent were used for stabilisation of the recanalised segment and the TIPS channel. After the interventional treatment the patients were observed in the intensive care unit for 24 hours, before they were transferred to the ward. Regular check-ups with repeated laboratory tests, clinical examination and USG examination were scheduled every three months during the first year, thereafter once a year. One boy received a TIPS, was additionally set up for shunt phlebography after six and twelve months.

**Paper IV**

In paper IV, interventional radiological treatment in 24 patients was evaluated retrospectively.

**Patients**

All patients had symptomatic PH secondary to occlusion of the splanchnic veins. There were 9 females and 15 males, from 9 months to 79 years old (mean 36.4 years). The diagnoses were based on USG, CT or MRI examinations. The symptoms and signs are stated in Table 4. Symptoms included gastrointestinal bleeding (n=15), intraperitoneal bleeding (n=1), abdominal pain, nausea, and/or vomiting (n=9) and jaundice secondary to biliary compression by portal collaterals (n=1). At the time of referral for treatment thrombocytopenia (n=14), splenomegaly (n=12), refractory ascites (n=4) and encephalopathy (n=4) also were present.

**Methods**

The procedures were performed under general anaesthesia (n=14) or local anaesthesia with systemic sedation (n=10). Vital signs such as heart rate, blood pressure and oxygen saturation were monitored during the interventions. Venograms were performed by injection of ionated contrast medium or carbon dioxide. Due to the preprocedural findings on USG, CT, or MRI, percutaneous transhepatic, transsplenic and/or transjugular access to the portal circulation was obtained according to the technique described earlier (paper I). Thrombolysis was performed by an infusion catheter positioned through the PV obstruction...
tion from the transjugular access. Tissue plasminogen activator was used at a rate of 1 mg/hour for 24 hours. Two different mechanical thrombectomy devices, Amplatz Thrombectomy Device (Microvena, White Bear Lake, MN, USA) or Arrow-Trerotola percutaneous thrombolytic device (Arrow International Inc., Reading, PA, USA) were used, inserted through the transhepatic or transjugular portal venous sheath. Hydrophilic guide wires and angiographic catheters were used to pass the venous occlusions. The used stents and stent-grafts are summarized in Table 5. When a transsplenic or transhepatic route was used the tract was embolised with coils and/or gelatine sponge. A partial splenic embolisation was accomplished to decrease inflow of blood to the portal system and/or decrease symptoms secondary to hypersplenism as described previously (paper I). If TIPS was necessary, modified technique was used according to the location and extension of the PVO. In several patients the puncture of the PV from the hepatic veins was performed towards the percutaneously inserted catheters, used as a target. All patients were kept in the intensive care unit for minimum of 24 hours after the procedures. Patients treated with TIPS or recanalisations were followed-up according to the routine at the institution where the intervention was performed. Additional information was obtained from records from medical journals, laboratory data and imaging studies. Patients without active bleeding, treated with stents or stent-grafts, received antiplatelet medication for six weeks.
### Table 4. Clinical presentation, cause and site of splanchnic venous obstruction.

<table>
<thead>
<tr>
<th>Number</th>
<th>Age</th>
<th>Sex</th>
<th>Symptoms and signs</th>
<th>Cause</th>
<th>Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>59</td>
<td>F</td>
<td>GIB</td>
<td>Chronic thrombosis</td>
<td>Main PV + Intrahepatic PVs</td>
</tr>
<tr>
<td>2</td>
<td>64</td>
<td>F</td>
<td>Refractory ascites, GIS</td>
<td>Tumor encasement</td>
<td>Main PV (partial) + SMV</td>
</tr>
<tr>
<td>3</td>
<td>34</td>
<td>M</td>
<td>GIB + GIS</td>
<td>Chronic thrombosis</td>
<td>Main PV + mesenteric veins</td>
</tr>
<tr>
<td>4</td>
<td>62</td>
<td>M</td>
<td>GIS</td>
<td>Acute thrombosis</td>
<td>Main PV</td>
</tr>
<tr>
<td>5</td>
<td>54</td>
<td>M</td>
<td>GIB</td>
<td>Acute + chronic thrombosis</td>
<td>Main PV</td>
</tr>
<tr>
<td>6</td>
<td>79</td>
<td>M</td>
<td>GIB, encephalopathy, thrombocytopenia</td>
<td>Chronic thrombosis</td>
<td>Main PV</td>
</tr>
<tr>
<td>7</td>
<td>43</td>
<td>M</td>
<td>GIB, splenomegaly, thrombocytopenia</td>
<td>Chronic thrombosis</td>
<td>Main PV</td>
</tr>
<tr>
<td>8</td>
<td>45</td>
<td>M</td>
<td>GIS, encephalopathy, thrombocytopenia</td>
<td>Chronic thrombosis</td>
<td>Main PV + Occluded TIPS</td>
</tr>
<tr>
<td>9</td>
<td>41</td>
<td>F</td>
<td>GIB</td>
<td>Chronic thrombosis</td>
<td>Main PV + Intrahepatic PVs</td>
</tr>
<tr>
<td>10</td>
<td>65</td>
<td>M</td>
<td>Intraperitoneal bleeding, ascites, encephalopathy, thrombocytopenia</td>
<td>Acute + chronic thrombosis</td>
<td>Main PV + Intrahepatic PVs</td>
</tr>
<tr>
<td>11</td>
<td>35</td>
<td>M</td>
<td>Ascites, GIS, splenomegaly, bleeding from PTC tube</td>
<td>External compression</td>
<td>Main PV</td>
</tr>
<tr>
<td>12</td>
<td>39</td>
<td>M</td>
<td>GIB, abdominal pain, thrombocytopenia</td>
<td>Chronic thrombosis</td>
<td>Main PV + SV + SMV</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GIB, splenomegaly, thrombocytopenia, GIS</td>
<td>Chronic thrombosis</td>
<td>Main PV + Intrahepatic PVs</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>--------------------------------------</td>
<td>-------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>13</td>
<td>23</td>
<td>M</td>
<td>Ascites, splenomegaly, thrombocytopenia, TIPS occlusion</td>
<td>Chronic thrombosis</td>
<td>Main PV + Occluded TIPS</td>
</tr>
<tr>
<td>14</td>
<td>49</td>
<td>F</td>
<td>Huge varices, thrombocytopenia</td>
<td>Chronic thrombosis</td>
<td>Main PV + Intrahepatic PVs</td>
</tr>
<tr>
<td>15</td>
<td>48</td>
<td>F</td>
<td>Splenomegaly, enlarged abdominal sc veins</td>
<td>Chronic thrombosis</td>
<td>Intrahepatic PVs</td>
</tr>
<tr>
<td>16</td>
<td>4</td>
<td>F</td>
<td>GIB</td>
<td>Chronic thrombosis</td>
<td>Intrahepatic PVs</td>
</tr>
<tr>
<td>17</td>
<td>0.75</td>
<td>F</td>
<td>GIB, splenomegaly, thrombocytopenia</td>
<td>Chronic thrombosis</td>
<td>Main PV</td>
</tr>
<tr>
<td>18</td>
<td>8</td>
<td>M</td>
<td>GIB, splenomegaly, thrombocytopenia</td>
<td>Chronic thrombosis</td>
<td>Main PV + SV</td>
</tr>
<tr>
<td>19</td>
<td>16</td>
<td>M</td>
<td>GIB, splenomegaly, thrombocytopenia</td>
<td>Chronic thrombosis</td>
<td>Main PV + SV</td>
</tr>
<tr>
<td>20</td>
<td>13</td>
<td>M</td>
<td>GIB, GIS, splenomegaly, thrombocytopenia</td>
<td>Chronic thrombosis</td>
<td>Main PV + Intrahepatic PVs</td>
</tr>
<tr>
<td>21</td>
<td>14</td>
<td>M</td>
<td>GIB, splenomegaly, thrombocytopenia</td>
<td>Chronic thrombosis</td>
<td>Main PV</td>
</tr>
<tr>
<td>22</td>
<td>24</td>
<td>F</td>
<td>GIS, jaundice, splenomegaly</td>
<td>Chronic thrombosis</td>
<td>Main PV</td>
</tr>
<tr>
<td>23</td>
<td>24</td>
<td>F</td>
<td>GIB, encephalopathy, thrombocytopenia, splenomegaly</td>
<td>Acute + chronic thrombosis</td>
<td>Main PV + SMV + SV</td>
</tr>
</tbody>
</table>

GIB: Gastrointestinal bleeding, GIS: Gastrointestinal symptoms, PV: Portal vein, SMV: Superior mesenteric vein, SV: splenic vein, TIPS: Transjugular intrahepatic portosystemic shunt
**Table 5: Interventions performed and outcome of patients with splanchnic venous obstruction.**

<table>
<thead>
<tr>
<th>Number</th>
<th>Access</th>
<th>Embolization</th>
<th>Recanalization</th>
<th>TIPS</th>
<th>Gradient before (mmHg)</th>
<th>Gradient after (mmHg)</th>
<th>Interval (months)</th>
<th>Improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>TJ</td>
<td>-</td>
<td>One 10x94 mm WS, one 25 mm Palmaz stent</td>
<td>Yes</td>
<td>13</td>
<td>4</td>
<td>0.25*</td>
<td>No</td>
</tr>
<tr>
<td>2</td>
<td>TJ</td>
<td>-</td>
<td>Two 12x40 mm SMART stents</td>
<td>No</td>
<td>20</td>
<td>5</td>
<td>12</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>TH</td>
<td>-</td>
<td>Two 10x40 Jomed stent-grafts</td>
<td>No</td>
<td>52</td>
<td>18</td>
<td>2*</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>TJ</td>
<td>-</td>
<td>PT, MT, 10x68 mm WS</td>
<td>Yes</td>
<td>31</td>
<td>14</td>
<td>24</td>
<td>Yes</td>
</tr>
<tr>
<td>5</td>
<td>TJ+TH</td>
<td>-</td>
<td>Three 10x38 mm Palmaz stents, 10x94 mm WS, 10x40 mm Symphony stent</td>
<td>No</td>
<td>22</td>
<td>12</td>
<td>12</td>
<td>Yes</td>
</tr>
<tr>
<td>6</td>
<td>TH</td>
<td>-</td>
<td>Two 12x40 mm SMART stents</td>
<td>No</td>
<td>19</td>
<td>2</td>
<td>8</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>TJ+TH</td>
<td>Partial splenic (70%)</td>
<td>10X94 mm WS, two 10x68 mm WS, 10x42 mm WS</td>
<td>Yes</td>
<td>15</td>
<td>6</td>
<td>1*</td>
<td>Yes</td>
</tr>
<tr>
<td>8</td>
<td>TJ+TH</td>
<td>-</td>
<td>10x94 mm WS, 10x68 mm WS</td>
<td>Yes (existing TIPS revised)</td>
<td>25</td>
<td>7</td>
<td>3</td>
<td>Yes</td>
</tr>
<tr>
<td>9</td>
<td>TJ+TH</td>
<td>-</td>
<td>Three 10x94 mm WS, 10x42 mm WS</td>
<td>Yes</td>
<td>30</td>
<td>5</td>
<td>1</td>
<td>Yes</td>
</tr>
<tr>
<td>10</td>
<td>TJ+TH</td>
<td>-</td>
<td>MT, two 10x94 mm WS, two 10x68 mm WS</td>
<td>Yes</td>
<td>35</td>
<td>8</td>
<td>0.1*</td>
<td>No</td>
</tr>
<tr>
<td>11</td>
<td>TH</td>
<td>-</td>
<td>12x40 mm SMART stent</td>
<td>No</td>
<td>26</td>
<td>18</td>
<td>3</td>
<td>Yes</td>
</tr>
<tr>
<td>12</td>
<td>TJ+TH</td>
<td>-</td>
<td>Three Fluency stent-grafts, two WS, MT</td>
<td>Yes</td>
<td>15</td>
<td>0</td>
<td>3*</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Procedure</td>
<td>Description</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>-----------</td>
<td>-------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>TJ</td>
<td>10x94 mm WS</td>
<td>Yes</td>
<td>13</td>
<td>4</td>
<td>4</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>TJ+TS</td>
<td>Two 10x80 mm Viatorr stent-grafts, 12x60 mm Viatorr stent-graft, 10x42 mm WS</td>
<td>Yes (existing TIPS revised)</td>
<td>24</td>
<td>32</td>
<td>24</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>TJ+TS</td>
<td>DIAGNOSTIC ONLY</td>
<td>No</td>
<td>32</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>TH</td>
<td>DIAGNOSTIC ONLY</td>
<td>No</td>
<td>11</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>TH</td>
<td>GE variceal</td>
<td>No</td>
<td>25</td>
<td>-</td>
<td>4</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>TH</td>
<td>Two 40 mm Palmaz stents</td>
<td>Yes</td>
<td>17</td>
<td>0</td>
<td>58</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>TS</td>
<td>Partial splenic (75%)</td>
<td>No</td>
<td>-</td>
<td>-</td>
<td>48</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>TS</td>
<td>Partial splenic (70%)</td>
<td>No</td>
<td>-</td>
<td>-</td>
<td>40</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>TJ+TS</td>
<td>Two 40 mm Jomed stent-grafts, 10x42 mm WS</td>
<td>Yes</td>
<td>28</td>
<td>11</td>
<td>36</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>TH</td>
<td>Partial splenic (65%)</td>
<td>No</td>
<td>21</td>
<td>0</td>
<td>24</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>TH</td>
<td>12x60 mm SMART stent, 12x40 mm SMART stent, MT</td>
<td>No</td>
<td>14</td>
<td>4</td>
<td>1</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>TJ+TH</td>
<td>Splenorenal shunt</td>
<td>MT, 12x40 mm WS, 10x68 mm WS, 10x100 mm Viatorr stent-graft, 10x80 mm Viatorr stent-graft</td>
<td>Yes</td>
<td>14</td>
<td>9</td>
<td>1</td>
<td>Yes</td>
</tr>
</tbody>
</table>

*Expired

Interventions for Portal Hypertension in Patients with Portal Vein Occlusion

Table 6. Activity in the region of interest drained by the right hepatic liver vein as a percentage of total liver activity

<table>
<thead>
<tr>
<th>Pig</th>
<th>Before</th>
<th>After TIPS</th>
<th>After stent-graft</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pig 1</td>
<td>30</td>
<td>34</td>
<td>22</td>
</tr>
<tr>
<td>Pig 2</td>
<td>40</td>
<td>52</td>
<td>47</td>
</tr>
<tr>
<td>Pig 3</td>
<td>47</td>
<td>49</td>
<td>41</td>
</tr>
<tr>
<td>Pig 4</td>
<td>50</td>
<td>49</td>
<td>40</td>
</tr>
<tr>
<td>Pig 5</td>
<td>40</td>
<td>38</td>
<td>30</td>
</tr>
</tbody>
</table>

Results

Experimental studies

Paper II

The pilot study showed reduced uptake of $^{99}$Tc$m$-HSA in the ROI after inflation of the balloon, which occluded the liver vein. In one pig, dislodgement of the catheter had occurred during transportation to the scintigraphy room and another pig died due to respiratory problems during the experiments. These two pigs were excluded from the data analysis. In one pig the stent-graft was placed too caudally and had to be extended with an additional stent-graft. Distribution of $^{99}$Tc$m$-HSA showed similar pattern on planar scintigraphic images. The results are summarized in Table 6.

Accumulation of $^{99}$Tc$m$-HSA calculated over a ROI was unchanged in all pigs after stent placement except for one pig, in which it increased ($p=0.25$ before vs after stent). After placement of a stent-graft the activity decreased in all pigs ($p=0.06$ after stent vs after stent-graft).

Paper III

Due to an anatomical variation, the hepatic vein was not completely blocked by the stent-graft in one pig and this animal was excluded from the study. In another pig the inserted stent-graft was too short and its bare part did not reach far enough into the portal vein. To optimize the flow in the shunt, an additional stent (12x80 mm Smart stent, Cordis) was inserted. One pig died of respiratory failure, just prior to the last radionuclide injection. This animal was included in the first part of the radionuclide study as well as in the histological assessments, but had to be excluded from the final part. One minute after the isotope injection post TIPS, decreased outflow was seen from the occluded vein, compared to the measurements obtained before TIPS. However, already after three minutes the flow...
was normalized. The values remained mainly unchanged in the studies after two weeks. Statistical analysis was not conclusive due to the limited number of animals.

Histological evaluation was done in five pigs. Four animals had normal acinar pattern, without any macroscopic evidence of fibrosis, steatosis, cirrhosis or sign of congestion. One animal had a different pattern and showed macroscopic cirrhosis, with marked infiltration of neutrophils, lymphocytes and plasma cells, findings most likely related to chronic changes. In two more samples, from two different pigs and from different lobes, there were light portal fibrosis with mild infiltration of neutrophils, lymphocytes and plasma cells, but no fibrosis around central veins. Also these changes were most likely unrelated to the experiment. Only one pig had a fully patent stent-graft. The remaining four stent-grafts were occluded to 75–100%.

**Clinical studies**

**Paper I**

All children had large gastro-oesophageal varices. Two had extensive PVO, which included the splenic vein. The other three children had a short PVO extending 3–4 cm from the liver hilum. The treatment is summarized in table 7.

In four children partial splenic embolisation was successfully performed. All children had fever and severe pain after the embolisation, which was treated by morphine chloride administration in three of them. One patient required epidural anaesthesia for two days. After 4–7 days the pain decreased and could be managed by oral analgetics for a few days. Transjugular puncture of the IPVB was attempted in four children, but further recanalisation from this approach was impossible in all of them. Percutaneous transhepatic access to the IPVB was feasible in four children. In one patient (patient no 1) stent recanalisation of the occluded segment of the PV was done and an additional stent was inserted due to re-stenosis 46 months after recanalisation. In another child (patient no 3) a guide-wire could be passed from the IPVB to the collaterals in the cavernous transformation, but could not be advanced further to the PV due to the tortuosity of these vessels. However, after dilatation and stenting of the stenosis between the IPVB and the cavernous transformation, a pressure gradient of 12 mm Hg disappeared and the inflow of the portal blood to the right liver lobe improved. Percutaneous trans-splenic puncture to the portal vein

<table>
<thead>
<tr>
<th>Patient</th>
<th>Recanalisation</th>
<th>Splenic embolisation</th>
<th>Reintervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Occluded segment of PV</td>
<td>Not necessary</td>
<td>Repeated balloon dilatation and insertion of additional stent</td>
</tr>
<tr>
<td>2</td>
<td>Not possible</td>
<td>70 % of caudal portion</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>Not possible</td>
<td>75 % of caudal portion</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>TIPS necessary</td>
<td>70 % of caudal portion</td>
<td>Repeated balloon dilatation and insertion of additional stent</td>
</tr>
<tr>
<td>5</td>
<td>Partial recanalisation</td>
<td>60 % of caudal portion</td>
<td>Intended new splenic embolisation</td>
</tr>
</tbody>
</table>
Interventions for Portal Hypertension in Patients with Portal Vein Occlusion

branches was performed in three children. In two children the splenic vein was occluded, but catheterization of the collaterals was possible. However it was not possible to pass the occlusion and these children were treated only by partial embolisation of the spleen.

In the third child (patient no 4) contrast injection confirmed large collaterals along the gallbladder and large gastro-oesophageal varices, also visualized previously at MRI and USG examinations. Only small, very peripheral portal vein branches remained open in the liver and the PV was occluded 2–3 cm outside liver hilum. Due to the high pressure gradient of 28 mm Hg between the portal vein and the systemic circulation, a portosystemic shunt was created. The puncture tract in the liver had partly an intraperitoneal route, although the PVO stretched outside the liver. To prevent intraperitoneal bleeding insertion of a 4 cm long, balloonexpandable stent-graft (Jomed) was intended in the intraperitoneal portion of the shunt channel. However, the first stent-graft was accidentally pushed out from the sheath into the splenic vein and could not be retrieved. This stent-graft had to be expanded and was left in the splenic vein. Subsequently, a similar stent-graft was inserted in the intended position. During placement of this stent-graft minor peritoneal bleeding occurred, but ceased as soon as the stent-graft was balloon expanded. The cranial portion of the shunt was kept open by a 10x40 mm Wallstent. A 24 mm long Palmaz stent was inserted distally to prevent migration of a stent-graft, stretching into the PV. All stents and stent-grafts were dilated with an 8x40 mm angioplasty balloon, which reduced the pressure gradient from the initial 28 to 11 mmHg. No other immediate complications were recorded. After six months shunt phlebography showed pronounced stenosis at the cephalic edge of the Wallstent in the hepatic vein. An additional 28 mm long Palmaz stent was placed through the stenosis and dilated with 10 mm-diameter balloon, which normalised the pressure.

Paper IV

Access to the portal circulation was obtained by percutaneous transhepatic (n=15), transsplenic (n=5), and transjugular (n=14) route. The site of occlusion was the main PV (n=22), with additionally occluded IPVB (n=8), mesenteric veins (n=4), and/or splenic vein (n=4). The cause of occlusion was chronic thrombosis (n=18), acute thrombosis (n=1), acute and chronic thrombosis (n=3), tumour encasement (n=1) and right PV compression by biliary stents (n=1) See table 4.

In two patients intervention were not attempted, due to findings on venograms. One of these patients turned out to be a possible candidate for liver transplant and in the other patient intervention was estimated too risky. Thus interventional treatment was performed in 22 patients. Another patient was also found to be a transplant candidate and only embolisation of oesophageal varices was done. Two patients were treated only by partial splenic embolisation. Recanalisation of occlusion with or without TIPS placement was carried out in 19 patients. See table 5.

Recanalised segment was stabilized with stents (n=14) or stent-grafts (n=5). A new TIPS (n=10) was placed in order to maintain adequate blood flow through the recanalised venous segment. In two patients, the existing occluded TIPS were recanalised to gain access into the occluded PV. In one of these patients puncture of the occluded TIPS was done using a Colapinto needle by transjugular approach. In the other patient, puncture of the occluded TIPS stent-graft by percutaneous transhepatic route was followed by advancement of a guidewire through the stent-graft towards the right atrium. Using through and through technique subsequent recanalisation of occluded TIPS and PV was possible. After recanalisation additional stents were deployed, covering the occluded PV segments and TIPS channel. Recanalisation of the splanchnic veins was successfully achieved in
all attempted patients at the completion of the procedures. After recanalisation, pressure gradient over occluded segments decreased in all patients but one, from 24 mmHg to 8 mmHg following treatment. In this patient, portal pressure remained unchanged after recanalisation and TIPS, while the right atrial pressure decreased. Despite good flow through in the recanalised channel and through the TIPS, the gradient increased. However, during follow-up and subsequent revisions the gradient decreased considerably. Successful mechanical thrombfragmentation was performed after failed pharmacological thrombolysis in one patient with acute thrombosis of the PV. Two patients with acute and chronic thrombosis and two patients, who developed acute thrombus during the procedure, were also successfully treated with mechanical thrombfragmentation. Partial embolisation of the spleen was performed in five patients in order to reduce symptoms secondary to hypersplenism and/or decrease inflow of blood to the PV system.

Three patients (13.6%) died within 30 days following the procedure. Two of them passed away due to continual bleeding. In one of them, bleeding was a result of hemorrhagic diathesis. In the other patient, the origin of intraperitoneal bleeding was not found. One patient died due to hepatorenal syndrome and sepsis. Another patient died eight weeks later, following development of intraperitoneal abscess. In one patient two days after the procedure, Doppler USG showed no flow through the TIPS, however, the bleeding stopped and re-intervention was considered unnecessary at that time. This patient expired three months later due to intractable gastro-intestinal bleeding. In these five patients further interventional radiological treatment was not indicated, due to their poor general condition.

Improvement of symptoms after procedure was seen in 91% of the treated patients. Follow-up of remaining patients ranged between 2 days and 48 months. Five patients required repeated stent placements secondary to occlusion or stenosis, 3–48 months after the initial recanalisation.
Discussion

In the normal splanchnic system, the intestinal, splenic, pancreatic and gastric venous drainage unite to form the PV. Pressure in the normal PV is slightly higher than in the systemic veins and the pressure gradient between the two systems generates filtration through the sinusoids in the liver. Obstruction of the flow in the PH leads to development of collaterals from the high pressure portal system to the low pressure systemic circulation. Varices may develop from these collaterals, especially around the oesophagus, stomach, rectum and umbilicus, and occasionally around the duodenum, jejunum or colon. Ascites, gastrointestinal bleeding, splenomegaly and HE are other findings associated with PH. When PH is caused by reasons other than obstruction in the liver parenchyma, good liver function may be present with preserved filtering of the blood and sufficient production of all necessary proteins.

Symptomatic PH due to hepatic or posthepatic obstruction is treated in different ways. The definitive treatment is liver transplantation, whereas symptomatic treatment includes several options; pharmacological therapy, endoscopic, surgical and interventional treatment. Introduction of the TIPS procedure was a breakthrough in the symptomatic treatment of hepatic and posthepatic PH. Further improvement in TIPS technique, including simultaneous embolisation of varices and the introduction of new devices, especially designed for TIPS, have improved long-time results. Splenic embolisation, which is another approach, may be accomplished to decrease inflow of the blood in the PV system. Balloon-occluded retrograde transvenous obliteration (BRTO), introduced in recent years, has further extended the possibilities of interventional treatment (Choi et al. 2003). Pathophysiologically two mechanisms will occur in patients with PVO, when the liver loses portal perfusion. The first consists of an arterial response, resulting in an immediate vasodilatation of the arterial bed. The second is a relatively rapid development of collateral veins, by-passing the occluded portion of the PV, resulting in cavernous transformation (Boyer et al. 2006; Harmanci et al. 2007). As a result of these compensatory mechanisms, the hepatic venous pressure gradient is initially preserved and the portal pressure is elevated proximal to the occlusion. The portal pressure will further increase over time with elevated risk of variceal bleeding.

The prevalence of PVO has been estimated to 1% in a material of more than 23,000 patients (Ögren et al. 2006). In this material, based on autopsies, 28% of the patients had cirrhosis, 67% had liver malignancy (primary or metastatic), 10% had inflammatory intraabdominal disease and only 3% had myeloproliferative disease. The cause of prehepatic obstruction in our material of 24 patients was chronic thrombosis \((n=18)\), acute thrombosis \((n=1)\), combined acute and chronic thrombosis \((n=3)\), tumour encasement \((n=1)\), and external compression of a biliary stent \((n=1)\). Acute thrombosis can be treated with transcatheter thrombolysis, sometimes in combination with mechanical thrombusfragmentation. Intra-arterial thrombolytic agents can also be infused in the superior mesenteric artery. Though the use of anticoagulation is under debate (Webster et al. 2005).

The splanchnic obstruction may be classified due to the extension and the localization of the thrombus. Most patients in paper IV had occlusion of the main PV \((n=22)\), with additionally occluded IPVB \((n=8)\), mesenteric veins \((n=4)\), and/or splenic vein \((n=4)\). Isolated occlusion of the IPVB was found in two patients. The incidence of cirrhosis and malignancy in the material was not investigated.

The goal for the medical treatment is to decrease the inflow of blood to the splanchnic circulation and/or dilate the mesenteric veins and thereby reduce the pressure gradi-
If the pressure gradient is kept below 10–12 mm Hg (Vorobioff et al. 1996) or a reduction of 25–50% of initial pressure gradient is achieved the risk of variceal bleeding is very low (Rössle et al. 2001). Interventional treatment of patients with PVO requires a different approach, to that of patients with intrinsic liver disease. TIPS is not the first option for patients with prehepatic obstruction, but additional TIPS is often necessary in patients where the IPVB are also occluded (Kori et al. 2006). Surgical shunts are sometimes used and selective shunts are favoured (Galambos et al. 1976).

In the treatment of PH, the access to the portal venous system depends on the patency of the PV and the possible extent and localisation of the occlusion. In a patient with a patent PV, the portal system can be reached by a transjugular approach. This is the traditional route to perform a TIPS (Richter et al. 1990) and is the method of choice if the IPVB are patent. In patients with very small or occluded IPVB, transjugular access can be very difficult or impossible and other possibilities must be chosen. Interventional treatment through a percutaneous transhepatic access was introduced by Lunderquist (Lunderquist et al. 1974), who performed percutaneous transhepatic embolisations of gastroesophageal varices. With the percutaneous technique, either by blind or USG guided puncture, a short distance access is provided to the portal circulation. This technique was used in our patients (n=15), in order to gain access to an occluded TIPS or to create a new shunt. In patients with large amounts of ascites laparocentesis is preferred prior to the transhepatic puncture. A patent paraumbilical vein can easily be punctured under USG guidance and be used as an entrance to the portal branches, a technique useful in hepatic PH. Transsplenic puncture to gain access to the PV system was performed in our material after partial splenic embolisation. A number of our patients had a catheter or a glide-wire inserted from a transsplenic approach, which was then used as a target during the attempts to pass an occlusion or to create a TIPS. In one of the children, where the PVO stretched outside the liver, the puncture tract had a partly intraperitoneal route. A guide-wire inserted by a TIPS catheter was caught by a goose-neck snare, inserted from a transsplenic puncture. When this child was treated, the Viatorr was not available and we used balloonexpandable stent-grafts to cover the extrahepatic portion of the shunt channel. During reintervention for hepatic vein stenosis in this patient, we did not know the possible consequences of occlusion of the hepatic vein when using a stent-graft and a bare stent was therefore used. Reported experiences in children were limited at that time (Citron et al. 1998; Heyman et al. 1997; Huppert et al. 2002). The management of this patient stimulated our interest to study the possible circulatory effects of a stent-graft and resulted in the experimental studies (paper II and III).

In case of prehepatic obstruction it is important, especially in children, to restore the portal flow through the liver, in order to maintain the hepatic functions of growth, exocrine and endocrine secretory functions etc. Therefore recanalisation was intended in all patients with PVO. This intervention may be complicated, especially if the occlusion has been longstanding and if cavernous transformation has been formed. Stents and stent-grafts should be used to support the recanalised segments. In patients with symptomatic PH, caused by intrinsic factors, TIPS has become a relatively common procedure. When we started our clinical studies, the stent-grafts dedicated for TIPS, were not available. Initial high rates of dysfunction, approximately 50% in a year (Sanyal et al. 1997), led to the improvement of the shunt devices. Stent-graft separate the shunt channel from transected bile ducts and blood vessels, which reduces the formation of pseudointimal hyperplasia (Haskal et al. 1992, Haskal et al. 1997, Szé et
Stent-grafts have also been used to stop haemorrhages after extra hepatic puncture of the portal vein in TIPS procedures (Broutzos et al. 2000). During the last decade different graft materials for the stent-grafts have been tested. Polyethylene terephthalate (polyester), polycarbonate urethane and silicone have been proven equal to or in some cases less adequate, than conventional TIPS, due to intrinsic thrombogenicity, excessive porosity and propensity to induce inflammatory reactions (Haskal et al. 1999; Tanihata et al. 1997; Bloch et al. 1998). The majority of trials have favoured the ePTFE covered stent-grafts (Haskal et al. 1999; Cejna et al. 2001; Rossi et al. 2004; Bureau et al. 2007). Since 2000, the ePTFE covered selfexpanding stent-graft, Viatorr, has been in commercial use. In order to obtain high patency rate in Viatorr, the ePTFE covered portion should stretch into the hepatic vein and up to the IVC. See fig 8. However, stent-grafts in this position block the outflow from the hepatic vein.

Prior to these clinical publications (paper I and IV) there were only few reports of re-establishing PV patency after recanalisation (Bezzi et al. 1995, Matsui et al. 1996; Cwikiel et al. 2000). In paper IV recanalisation with stents and stent-grafts as the only interventional treatment was performed in seven patients. In cases of slow portal flow after the recanalisations or occlusion of IPVB combined treatment with TIPS was necessary (n=10). Partial splenic embolisations were performed as an isolated treatment (n=2) or in combination with recanalisation (n=3). In the two patients where partial splenic embolisation was the only feasible treatment, recanalisation was not possible. In these children embolisation provided enough reduction in PV pressure to stop the bleeding and endoscopic follow-up showed reduction of varices. Embolisation of gastro-oesophageal varices was the only treatment in one patient, with improvement in symptoms. Reduction of mean pressure gradient was seen in all but one of the treated patients, with a reduction from 24 mmHg to 8 mmHg following treatment. Improvement of symptoms was observed in 91% of the treated patients. Two patients were not treated at all. One was a suitable transplant candidate and in the case of the other patient the risk of intervention was too high.

Two experimental studies were performed (paper II and III), where we wanted to evaluate if occlusion of the hepatic vein by a stent-graft had any negative consequences for the liver circulation or the liver parenchyma. Possible effects had not been studied previously. Meanwhile segmental ischemia after PTFE covered stent-graft was described by Bureau et al. 2002, but without any sequel for the patient. We could only perform studies in a relatively small number of animals, due to the limited number of stent-grafts provided by the company and due to the complexity of the experiments. TIPS creation was successful in all but one animal, which was excluded from analysis do to an anatomic variant. Due to the limited number of animals statistical evaluation did not show significant values. We could therefore only demonstrate a tendency.
Conclusion

Interventional treatment of patients with PH and occlusion of splanchnic veins is feasible, but the treatment must be individualised. On occasion, recanalisation in combination with TIPS gave good results with improvement of symptoms and reduction of pressure gradients.

Stent-grafts used for TIPS have no long-lasting negative effects, neither on the liver circulation, nor on the liver parenchyma.

Future perspectives

TIPS has been in clinical use for nearly 20 years and has almost completely replaced surgical shunts. Early absolute contraindications, like portal vein thrombosis or Budd-Chiari syndrome have become relative and new indications have emerged.

Transplantation is the curative treatment for a patient with liver disease, whereas TIPS represents an alternative management. TIPS may also be useful prior to major abdominal surgery to prevent intra- and postoperative complications. Obstruction in the splanchnic veins usually requires other forms of treatment. We showed the advantage of a more aggressive management in patients with prehepatic obstruction. Further improvement of these methods is desirable. Development of new shunt devices e.g. longer stent-grafts suitable for treatment of intra- and extrahepatic PVO, can be expected. Interventions with, or in combination with, methods like USG and MRI which are not using ionising radiation are desired, in order to limit the radiation doses to both the patient and the interventionalist.
Populärvetenskaplig sammanfattning

Bakgrund:

Blod från tarmarna, magsäcken, mjälten och bukspottskörteln flyter samman till portavenen. Vid vissa sjukdomstillstånd i levern får man en ökning av trycket i portavenen, som står för större delen av leverens blodtillförsel. Detta tillstånd kallas för portal hypertension, PH, och kan vara orsakat av förändringar i levern eller i blodtillförseln till eller från levern. Hos barn är den vanligaste orsaken förändringar i blodtillförseln, som t ex inflammation i portavenen, medan orsaken hos vuxna domineras av förändringar i levervävnaden. Med tryckökningen i portavenen följer en hel del komplikationer som kan vara potentiellt livshotande, t ex blödning i blodkärl i anslutning till magsäck och matstrupe. Man får oftast även en förstoring av mjälten, som påverkar blodets levringsförmåga. PH är ofta svårbehandlad, p g a omfördelningen av flödet i portakärlet. Om inte sjukdomstillståndet svarar på sedvanlig behandling t ex medikamentell, görs ibland en s k TIPS, transjugular intrahepatiskt portosystemisk shunt. Detta är en konstgjord förbindelse, shunt, mellan leverens portakretslopp och systemcirkulationen, som gör att blodet kan passera levern, utan att behöva flöda igenom levervävnaden. Man kan då förhindra att blodet stockar sig och kan på så sätt minska trycket i de kärl som förser portavenen med blod. TIPS är en metod som infördes i början av 1990-talet och man använde sig initialt av stentar (ett slags metallnät) för att hålla den konstgjorda kanalen öppen. På senare tid har man mest använt en s k stent-graft, ett metallnät som är omgivet av ett semipermeabelt material, som har bättre långtids-effekt än bara metallnätsbehandling.

Portavenstrombos innebär att portakärlen täpps till, helt eller delvis, i hela eller delar av tillflödet. Detta är ett ovanligt tillstånd som ofta behöver en annan behandling än den vid PH, och kan i en del fall kompletteras med TIPS. Bakomliggande orsak kan vara lever-sjukdom (fr a cirros), tumörsjukdom i buken eller rubbning i blodets levningsförmåga. En stent-graft täpper till avflödet från levern till systemcirkulationen, vilket skulle kunna ha negativa effekter på leverns cirkulation hos patienter, som redan har nedsatt funktion i levern.

Utförda studier och resultat:


I den andra experimentella studien undersökte vi om stent-graften påverkade det venösa avflödet, dels direkt efter TIPS, och dels vid upprepning av försöket efter två veckor. Då undersöktes även levern histopatologiskt, där leverens struktur bedömdes i mikroskop. Resultatet visade att det direkta efter insättningen av en stent-graft för TIPS fanns en viss nedsättning av avflödet av blod, som i det närmaste normaliserades redan efter tre minuter.

De två andra artiklarna är studier som sammanfattar resultat och uppföljning av patienter, som behandlats med interventionella ingrepp. Den första studien omfattar barn som behandlats p g a tilltäppning av portavenen. Den andra kliniska studien är retrospektiv och omfattar ett patientmaterial på 24 patienter, som behandlats med interventionella metoder p g a portavens tilltäppning och portal hypertension.

Studierna har visat att interventionell behandling av patienter med portal hypertension och tilltäppning av portavenen eller dess tillförande kärl är möjlig att utföra och att användning av stent-grafter vid TIPS inte har några långtidsverkande negativa effekter på levercirkulationen.
Acknowledgements

I want to express my sincere gratitude to all colleagues, co-workers, family and friends, who in different ways assisted me in completing this thesis. Especially I want to thank:

Associate professor Wojciech Cwikiel, my supervisor in my academic work, tutor in interventional radiology and friend, who introduced me to interventions and research. Thank you for your never ending enthusiasm, help and positive input any time of the day and anywhere in the world……..

My present head of departments, Peter Leander and Martin Malina, and current professors Olle Ekberg and Krassi Ivancev, for encouragement and for giving me time.

My former head of departments, Hans Stridbeck and Peter Hochbergs for support in interventional radiology.

All the colleagues at the gastrointestinal units, Lund and Malmö University Hospitals and at the endovascular unit, Malmö University Hospital, for friendship and collaboration.

Associate professor Christer Lundstedt, for believing in me when I made my first attempts in interventions.

My co-author, Lennart Bergqvist for explaining the role of radionuclides.

Peter Mangell, for friendship and practical advice with this book.

My friends Vicky and Anders Nilsson, for language assistance and “keep cool” attitude.

Lennart, my husband and my love, for encouragement, enormous patience and never ending support.

Our children Axel and Hedvig, who make me see what is important in life. Thank you for borrowed time!
References


Burroughs AK, Vangeli M. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary


Interventions for Portal Hypertension in Patients with Portal Vein Occlusion


Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK. Transjugular intrahe-
Interventions for Portal Hypertension in Patients with Portal Vein Occlusion


Interventions for Portal Hypertension in Patients with Portal Vein Occlusion


